Back to Results
First PageMeta Content
Immune system / Monoclonal antibodies / Medicine / Biology / Immunology / Epithelial cell adhesion molecule / Immunogenicity


A PHASE I STUDY OF VB6-845, AN ANTI-EpCAM FUSION PROTEIN TARGETING ADVANCED SOLID TUMOURS OF EPITHELIAL ORIGIN: PRELIMINARY RESULTS M. Kowalski1, L. Brazas1, R. Zaretsky1, M. Rasamoelisolo2, G. MacDonald2, W. Cuthbert1,
Add to Reading List

Document Date: 2013-03-14 08:27:58

Open Document

File Size: 11,39 KB

Share Result on Facebook

City

Mississauga / Winnipeg / /

Company

Viventia Biotech Inc. / 2Viventia Biotech Inc. / CTC AE / /

MedicalCondition

fever / epithelial tumours / EpCAM-positive tumors / advanced epithelial tumours / disease / hypoalbuminemia / carcinoma / tumours / hypotension / /

ProvinceOrState

Manitoba / /

Technology

pharmacokinetics / /

SocialTag